Bone Biologics Corporation
BBLG
$1.75
-$0.01-0.57%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -8.59% | -8.26% | -21.96% | -17.12% | 0.54% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 6.08% | -13.35% | -39.39% | -55.25% | -59.98% |
| Operating Income | -6.08% | 13.35% | 39.39% | 55.25% | 59.98% |
| Income Before Tax | 4.70% | 17.56% | 30.16% | 54.04% | 36.35% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 4.70% | 17.56% | 30.16% | 54.04% | 36.35% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 4.70% | 17.56% | 30.16% | 54.04% | 36.35% |
| EBIT | -6.08% | 13.35% | 39.39% | 55.25% | 59.98% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 84.26% | 65.66% | 73.16% | 92.78% | 84.76% |
| Normalized Basic EPS | 75.63% | 81.92% | 84.60% | 95.38% | 90.15% |
| EPS Diluted | 84.26% | 65.66% | 73.16% | 92.78% | 84.76% |
| Normalized Diluted EPS | 75.63% | 81.92% | 84.60% | 95.38% | 90.15% |
| Average Basic Shares Outstanding | 389.27% | 301.50% | 363.67% | 382.16% | 370.20% |
| Average Diluted Shares Outstanding | 389.27% | 301.50% | 363.67% | 382.16% | 370.20% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |